Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 24.09.2020 | 10:50

Aladdin Healthcare Technologies will obtain an equity stake in public spinoff No-Age Biotech Inc. at TSX, aimed to combat age-related diseases

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous/Investment
24.09.2020 / 10:50
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies will obtain an equity stake in public spinoff No-Age Biotech Inc. at TSX, aimed to combat age-related diseases

- Aladdin has agreed to obtain a 25% equity stake in No-Age Biotech Inc., publicly traded spinoff at TSX, in late 2020.

- No-Age Biotech will be focused on the development of therapeutics to combat age-related diseases.

- Aladdin plans to develop a bespoke drug discovery platform to be contributed to No-Age Biotech in exchange for its stake.

- No-Age Biotech will be targeting an initial valuation of $50 - $75 million or their Series A investment round.

BERLIN/LONDON, September 24, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has agreed to obtain an equity stake in a spin-off company at the TSX (Toronto Stock Exchange) in late 2020. The spinoff has just been established and will be named No-Age Biotech Inc. The deal is subject to final terms that will be agreed in October this year. Aladdin will inform the capital market about the agreement with a further press release at an appropriate time.

Among the other founding shareholders, there are renowned and experienced professionals in the field of age-related diseases: Professor David Rubinsztein, Fellowship of the Academy of Medical Sciences and Fellow of the Royal Society, who is the Deputy Director of Cambridge Institute for Medical Research, University of Cambridge; NO-Age, a Norwegian integrated, interdisciplinary, center for human ageing research at international top level.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "Aladdin plans to develop a bespoke drug discovery platform which we intend to contribute to No-Age Biotech in exchange for the 25% stake. We also expect to become the exclusive AI provider to No-Age Biotech and generate an annual fee for both development and management of the AI platform, therefore bringing significant potential value to Aladdin."

Aladdin has already achieved milestones in drug development against Alzheimer's and other age-related diseases, marking a new era for a faster and optimized identification of drug targets. In May this year, the Company announced the development of new mitophagy inducers through a novel system for virtual drug screening based on Artificial Intelligence, which is actually a key component of Aladdin's drug development platform (AIDD). This new agreement confirms again Aladdin's capability to play a relevant role in the worldwide scientific progress with its self-developed AI Drug Discovery platform AIDD and to improve the health conditions of patients with age-related and neurodegenerative diseases.

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone : +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330

24.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

„Eine Investition in Mutares lohnt sich“

Mutares ist ein europaweit führender Private-Equity-Investor, der sich auf Sondersituationen wie Abspaltungen von großen Konzernen oder Turnaround- und Nachfolgesituationen spezialisiert hat. Ziel ist es, mit den Investments einen Return auf das eingesetzte Kapital von 7 bis 10 zu erzielen. Mit der jüngsten Mittelfristprognose hat der Münchner Finanzinvestor auf Basis von 5 Mrd. Euro Konzernumsatz eine Nettorendite für die börsennotierte Holding von 1,8 bis 2,2 % in Aussicht gestellt. In der Mitte der Zielspanne wird somit ein Nettogewinn von circa 100 Mio. Euro anvisiert. Hauck & Aufhäuser hat in der jüngsten Analyse ein Buy-Rating mit Kursziel für Mutares von 37,50 Euro ausgegeben.

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

FORTEC Elektronik Aktiengesellschaft

Original-Research: FORTEC Elektronik AG (von Montega AG): Kaufen

23. September 2021